Michael Plopper
San Diego, CANPI 1427121524
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,750 of the $37,495 with a category attached, or 74.0%. Johnson & Johnson accounts for 96.3% of it on its own, with 3 other manufacturers making up the rest.
Across 60 payments — averaging $624.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$36K
- Eisai Inc.$1K
- Vanda Pharmaceuticals Inc.$31
- Neurocrine Biosciences, Inc.$17
Across 465 payments — averaging $15,633 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$3.9M
- Eli Lilly$2.5M
- Janssen Scientific Affairs, LLC$400K
- Novo Nordisk AS$124K
- UCB SA$107K
- Janssen Research & Development, LLC$106K
- plus $115K from 6 others
What the payments were for
- Speaking & faculty fees$27,75074%
- Travel & lodging$8,23722%
- Food & beverage$1,5084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 48 | $36,107 |
| Eisai Inc. | 10 | $1,341 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$35,411
- INVEGA SUSTENNA$110
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.